In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients

References

• FekaduG, ChowDY, YouJHS. The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art. Expert Opin Pharmacother. 2021;1–10. doi:10.1080/14656566.2021.1967930
   Web of Science ®Google Scholar
• DaleyCL, CamineroJA. Management of multidrug-resistant tuberculosis. Semin Respir Crit Care Med. 2018;39(3):310–324. doi:10.1055/s-0038-166138330071546
   PubMed Web of Science ®Google Scholar
• SeungKJ, KeshavjeeS, RichML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863. doi:10.1101/cshperspect.a01786325918181
   PubMed Web of Science ®Google Scholar
• FaridgoharM. Finding new ways to combat multidrug-resistant tuberculosis. Microb Drug Resist. 2020;26(1):71–80. doi:10.1089/mdr.2018.035331517569
   PubMed Web of Science ®Google Scholar
• CamineroJA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J. 2005;25(5):928–936. doi:10.1183/09031936.05.0010300415863653
   PubMed Web of Science ®Google Scholar
• YanL, KanX, ZhuL, et al. Short-course regimen for subsequent treatment of pulmonary tuberculosis: a prospective, randomized, controlled multicenter clinical trial in China. Clin Ther. 2018;40(3):440–449. doi:10.1016/j.clinthera.2018.01.01329519716
   PubMed Web of Science ®Google Scholar
• SantosNCS, ScodroRBL, LealDC, et al. Determination of minimum bactericidal concentration, in single or combination drugs, against Mycobacterium tuberculosis. Future Microbiol. 2020;15:107–114. doi:10.2217/fmb-2019-005032064924
   PubMed Web of Science ®Google Scholar
• Caleffi-FerracioliKR, MaltempeFG, SiqueiraVL, CardosoRF. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method. Tuberculosis. 2013;93(6):660–663. doi:10.1016/j.tube.2013.09.00124083948
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia Spp., And Other Aerobic Actinomycetes. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• ZhuLZ, FuY, ChuNH, et al. [A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2006;29(8):520–523. Chinese.17074263
   PubMedGoogle Scholar
• ZongZ, JingW, ShiJ, et al. Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis in China. Antimicrob Agents Chemother. 2018;62(8):e00165–18. doi:10.1128/AAC.00165-1829844043
   PubMed Web of Science ®Google Scholar
• LiG, XuZ, JiangY, et al. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. Int J Antimicrob Agents. 2019;54(5):642–646. doi:10.1016/j.ijantimicag.2019.06.00231200023
   PubMed Web of Science ®Google Scholar
• CobanAY, BilginK, UzunM, DurupinarB. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates]. Mikrobiyol Bul. 2009;43(2):293–297. Turkish.19621615
   PubMed Web of Science ®Google Scholar
• Rey-JuradoE, TudóG, de la BellacasaJP, EspasaM, González-MartínJ. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2013;41(3):278–280. doi:10.1016/j.ijantimicag.2012.11.01123312604
   PubMed Web of Science ®Google Scholar
• BhusalY, ShiohiraCM, YamaneN. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2005;26(4):292–297. doi:10.1016/j.ijantimicag.2005.05.00516150578
   PubMed Web of Science ®Google Scholar
• ChengA, TsaiYT, ChangSY, et al. In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63(4):e02234–18. doi:10.1128/AAC.02234-1830670428
   PubMed Web of Science ®Google Scholar
• WuX, YangJ, TanG, et al. Drug resistance characteristics of mycobacterium tuberculosis isolates from patients with tuberculosis to 12 antituberculous drugs in China. Front Cell Infect Microbiol. 2019;9:345. doi:10.3389/fcimb.2019.0034531828045
   PubMed Web of Science ®Google Scholar
• PontaliE, RaviglioneMC, MiglioriGB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035. doi:10.1183/16000617.0035-201931142549
   PubMed Web of Science ®Google Scholar
• ChaeH, ShinSJ. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development. J Microbiol. 2018;56(5):300–311.29721826
   PubMed Web of Science ®Google Scholar
• NaidooA, ChirehwaM, McIlleronH, et al. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother. 2017;72(5):1441–1449. doi:10.1093/jac/dkx00428175315
   PubMed Web of Science ®Google Scholar
• LiuY, PertinezH, DaviesGR, GillespieSH, CoatesAR, HuY. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent mycobacterium tuberculosis in the Cornell mouse model. Antimicrob Agents Chemother. 2018;62(7):e00190–18. doi:10.1128/AAC.00190-1829661869
   PubMed Web of Science ®Google Scholar
• GillespieSH. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev. 2016;25(139):19–28. doi:10.1183/16000617.0085-201526929417
   PubMed Web of Science ®Google Scholar
• ZhangT, JiangG, WenS, et al. Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis. Infect Drug Resist. 2019;12:825–829. doi:10.2147/IDR.S20069731114264
   PubMed Web of Science ®Google Scholar
• JohansenMD, DaherW, Roquet-BanèresF, et al. Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64(11):e00363–20. doi:10.1128/AAC.00363-2032816730
   PubMed Web of Science ®Google Scholar
• FarhatMR, SixsmithJ, CalderonR, HicksND, FortuneSM, MurrayM. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2019;74(6):1477–1483. doi:10.1093/jac/dkz04830793747
   PubMed Web of Science ®Google Scholar
• AlfarisiO, AlghamdiWA, Al-ShaerMH, DooleyKE, PeloquinCA. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Expert Rev Clin Pharmacol. 2017;10(10):1027–1036. doi:10.1080/17512433.2017.136631128803492
   PubMed Web of Science ®Google Scholar
• TempleME, NahataMC. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother. 1999;33(11):1203–1210. doi:10.1345/aph.1845010573321
   PubMed Web of Science ®Google Scholar
• GoldsteinBP. Resistance to rifampicin: a review. J Antibiot (Tokyo). 2014;67(9):625–630. doi:10.1038/ja.2014.10725118103
   PubMed Web of Science ®Google Scholar
• RothsteinDM. Rifamycins, alone and in combination. Cold Spring Harb Perspect Med. 2016;6(7):a027011. doi:10.1101/cshperspect.a02701127270559
   PubMed Web of Science ®Google Scholar